Larazotide acetate compositions
The invention provides crystalline forms of the peptide Gly-Gly-Val-Leu-Val-Gln-Pro-Gly (SEQ ID NO 1), and salts of the peptide, which may further have associated water molecules. These salts and hydrated salts of the peptide and compositions comprising these materials have advantageous pharmaceutical properties.
1. A crystalline acetate salt of the peptide Gly-Gly-Val-Leu-Val-Gln-Pro-Gly (SEQ ID NO:1) having an XRPD pattern comprising peaks at 9.08±0.2 degrees 2θ, 9.52±0.2 degrees 2θ, 10.34±0.2 degrees 2θ, and 14.24±0.2 degrees 2θ.
2. A pharmaceutical composition comprising or prepared with the crystalline peptide salt of claim 1 .
3. The crystalline acetate salt of claim 1 further comprising one or more of the following peaks: 18.23±0.2 degrees 2θ, 19.08±0.2 degrees 2θ and/or 21.31±0.2 degrees 2θ.
4. The crystalline acetate salt of claim 3 having an XRPD pattern comprising peaks at 14.24±0.2 degrees 2θ and 18.23±0.2 degrees 2θ.
5. The crystalline acetate salt of claim 1 , wherein the acetate is present at a concentration of from about 20 to 30 mole %/mole of peptide.
6. The crystalline acetate salt of claim 5 , wherein the acetate is present at a concentration of less than about 15 mole %.
7. The crystalline acetate salt of claim 6 , wherein the acetate is present at a concentration of less than about 10 mole %.
8. The crystalline acetate salt of claim 7 , wherein the acetate is present at a concentration of between about 4 to about 8 mole %.